In contrast, bazedoxifene acts as a selective estrogen receptor modulator and has been shown to inhibit the IL-6/GP130/STAT3 signaling cascade, which is a key proinflammatory and pro-angiogenic pathway contributing to OHSS. The gene discussed is IL6; the disease is ovarian hyperstimulation syndrome.